Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

References

• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):1–10. doi:10.1016/S0140-6736(20)31286-1.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33(7):1341–1348. doi:10.1111/jdv.15574.
   PubMed Web of Science ®Google Scholar
• Maarouf M, Saberian C, Lio PA, et al. Head-and-neck dermatitis: diagnostic difficulties and management pearls. Pediatr Dermatol. 2018;35(6):748–753. doi:10.1111/pde.13642.
   PubMed Web of Science ®Google Scholar
• Lio PA, Wollenberg A, Thyssen JP, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943–948. doi:10.36849/JDD.2020.5422.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson B, Abuabara K, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023;89(3):519–528. doi:10.1016/j.jaad.2023.04.052.
   PubMed Web of Science ®Google Scholar
• Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150–157. doi:10.1111/1346-8138.14116.
   PubMed Web of Science ®Google Scholar
• Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046–1055. doi:10.1111/jdv.18849.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1–e20. doi:10.1016/j.jaad.2022.12.029.
   PubMed Web of Science ®Google Scholar
• Pao-Ling Lin C, Gordon S, Her MJ, et al. A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor. J Am Acad Dermatol. 2019;80(5):1451–1453. doi:10.1016/j.jaad.2018.10.054.
   PubMed Web of Science ®Google Scholar
• Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340–357. doi:10.1111/exd.13514.
   PubMed Web of Science ®Google Scholar
• Jaros J, Hendricks AJ, Shi VY, et al. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020;31(3):169–177. doi:10.1097/DER.0000000000000590.
   PubMed Web of Science ®Google Scholar
• Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541–549.e2. doi:10.1016/j.jaad.2014.11.024.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Christen-Zach S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi:10.1111/jdv.16892.
   PubMed Web of Science ®Google Scholar
• Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. doi:10.4161/jkst.24137.
   PubMedGoogle Scholar
• Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217.e13–228.e13. doi:10.1016/j.cell.2017.08.006.
   Web of Science ®Google Scholar
• Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–3117. doi:10.1182/blood-2009-04-214957.
   PubMed Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–872. doi:10.1016/j.jaad.2021.04.085.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11–18. doi:10.1034/j.1600-0625.2001.100102.x.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–949. doi:10.1111/j.1365-2133.1995.tb16953.x.
   PubMed Web of Science ®Google Scholar
• Glazenburg EJ, Mulder PG, Oranje AP. A statistical model to predict the reduction of lichenification in atopic dermatitis. Acta Derm Venereol. 2015;95(3):294–297. doi:10.2340/00015555-1881.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract. 2019;7(8):2699.e7–2706.e7. doi:10.1016/j.jaip.2019.05.055.
   Web of Science ®Google Scholar
• Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27–33. doi:10.1159/000365390.
   PubMed Web of Science ®Google Scholar
• Simpson EL, de Bruin-Weller M, Eckert L, et al. Responder threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019;9(4):799–805. doi:10.1007/s13555-019-00333-2.
   PubMed Web of Science ®Google Scholar
• Glatz M, Bosshard PP, Hoetzenecker W, et al. The role of Malassezia spp. In atopic dermatitis. J Clin Med. 2015;4(6):1217–1228. doi:10.3390/jcm4061217.
   PubMed Web of Science ®Google Scholar
• He D, Han Y, Wu H, et al. Treatment of atopic dermatitis using topical antifungal drugs: a meta-analysis. Dermatol Ther. 2022;35(12):e15930. doi:10.1111/dth.15930.
   PubMed Web of Science ®Google Scholar
• Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312–1315. doi:10.1001/jamadermatol.2019.2613.
   PubMed Web of Science ®Google Scholar
• Alexis A, de Bruin-Weller M, Weidinger S, et al. Rapidity of improvement in signs/symptoms of moderate-to-severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE study. Dermatol Ther. 2022;12(3):771–785. doi:10.1007/s13555-022-00694-1.
   Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023;34(1):2212095. doi:10.1080/09546634.2023.2212095.
   PubMed Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008–1016. doi:10.1016/j.jaad.2022.09.060.
   PubMed Web of Science ®Google Scholar